Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Mulholland should get the ok any day now for CYDY to up lift to NAZ. The short sellers might try one more attack on the long stock holders. I hope Nader keeps the up list notification in his pocket and does a surprise up list over night after the next short attack. Maybe that and some piece of good news to release the morning of the first day of trading under the temporary ticker CYDYD. No shares to borrow to roll over the shares held short and all existing short shares would need to be covered.
Brokers usually to the force covering for margin calls starting one hour before the closing bell. CYDY is not marginable but a short sale is always on margin. Should we see continued spikes in price time a sustained series of gains this will force shorts covering.
CYDY is in the power zone! Beastmode. RSI 75% and rising. This two days of big gains are going to show up on a lot of stock raders. When CYDY hits $5 it will hit Tutes radars seeing this launch it might be a MUST OWN stock for biotech portfolios especially with up list to NAZ and an EUA.
2020 the last year CYDY trades on the OTC. 2021 the first year of CYDY revenues.
Feel the heat! The next major catalyst could be up lift to NAZ. The big joy for longs will be waking up in just a few days and see the ticker changed to CYDYD the temporary ticker for the days long transition. For shorts it will mean that they will be forced to cover during those first few transition days. I believe Nader will pull a surprise up lift as he has some justified animosity towards short sellers.
That is what AVXL did on its up lift to NAZ in 2015. It caused the stock to skyrocket.
Now here this! Pfizer vaccine is have some allergic reactions in a small number of patients. Allergic reaction = cytokine storm. There needs to be a treatment for the allergic reaction/cytokine storm for the vaccine program to continue as planned. LEronlimab needs to be immediately deployed for this with some doses going along with the vaccine to be on site already in case of allergic reaction.
If it was the CRO or Samsung that took shares instead of cash that is double good news. Either way it is cash or pay down of liabilities.
Another Form D 350000 shares at yesterdays price $3.36 for another $1.176 mil. That might be the cash needed to uplist to NAZ.
BAM! That's what I am talkin' 'bout. If CYDY does this on enrollment what is it gonna do on results then EUA?
Volume precedes price.
Well don't look a gift horse in the mouth except to check the numbers tattooed there. AVXL is a better buy today @ 5.82vs a few days ago at $5. Pros will see that and start buying this today.
The 10Q is due for release. That should be the next shoe to drop.
7.7 million shares held short. Most of those might be traded back and forth today. Covering and re-shorted at the higher water mark. That is actually good that they will likely reshort as it help put a higher floor into the stock price as profits will be taken or buy stops initiated by covering on share price at a higher price later.
It is very easy for the market makers to walk it back down premarket. Never good to put to much reliance on premarket action except maybe to sell a little on the initial spike. The stock should re-inflate in regular trading.
Your post of that scientific publication reviewing the importance of CCR5 was the most important post I read her in weeks. It shows that CYDY is likely to grow into a very large Company over time given all the indication for Leronlimab. This is serious outside independent scientists backing up what CYDY has been saying about the many indications. Once it is approved for Covid19 many scientists University and Public Health based will start to study LERONLIMAB in these other viruses costing CYDY nothing except the product they donate while CYDY spends its money on Cancer, Nash, GraftvHost and others.
This could truly be a bigger franchise than Keytuda or even Humira which is $20 billion annual in sales. AbbVie and Merck will be jealous of any BP that can get there hands on Leronlimab.
Leron has such shocking potential that no one can believe it. Miracles don't happen. But they do some times haphazardly as the chance discovery of penicillin which changed medicine forever. Now comes Leronlimab doing for virus treatments what penicillin did for bacterial infections.
Will there be other CCR5 drugs, sure. But Leron is safe and has a massive head start.
If CYDY is bought out by a BP that company might double its market cap over a few years as well as pay larger dividends. I hope it will be a buyout for stock only.
Hush hush...I am still accumulating.
Wow! Chap 2.3 Leronlimab in Covid19 - Patterson Study
Chap 3.0 CCR5 in HIV
Chap 3.1 CCR5 in others West Nile, (no meds now) Influenza (move over Tamaflu) HPV ( a vaccine now) Hep B (no effective meds now huge research efforts under way) Hep C ( current meds) Polio ( only Vaccines)Dengue Fever ( epidemic in Indonesia and parts of Philippines - no effective meds) other dangerous viruses.
( my take- LeRonLiMab might be a silver bullet treatment for many viruses and prevent HIV and many others - blanket protection)- this article was just published Nov 2020
( ) are my comments ...
Hush hush...I am still accumulating stock.
There is a good chance the share price will jump if there is no warrant extension because it means the Company has the data and it will be released soon. Anyone paying attention would realize low chance of bad data. Why would warrant holder sell? Traders would buy pushing price up and that would cause shorts to start covering, increasing price further resulting in day traders buying and speculators thinking news leak causing a feeding frenzy for shares. Some selling might take a hold over $2. Who knows? Not me, but I will load up on any dip.
Friday was low volatility. John Bollinger's theory is high volatility follows periods of low volitility. Next week is going to be fun and profitable. I hope it rises high followed by a super vicious short attack followed by good TLD released the next day after the short attack. Time for Linda to get revenge on Phase Five Research and their ilk.
That is what happened to Immunomedics cancer drug. They got accelerated approval for immediate use and were in confirmatory trials when they were bought out by Gilead for 21 Billion dollars.
Would it not be ironic if it turns out the cure for vaccine side effects turns out to be Leronlimab? Especially since they could have used Leron to start with with an OWS investment to ramp production of Leron. Pay CytoDyn now or pay more later. Leronlimab!!
Excellent thank you. That makes my decision to continue to further accumulate easier. I love to average up. Mathematically averaging up reduces risk with appropriate mental stops in any decline except a major gap down.
If NWBO already has the data and it is not good it seems they would have made a disclosure to avoid allegations of fraud. This analysis shows that it is highly unlikely that NWBO did not acheive the primary endpoint.
I don't know but it maybe that going over the authorized shares does not cause a problem except they could not do another offering because the SEC would not grant effectiveness to a new prospectus, so therefore they would not even try. So maybe for shareholders not wanting further dilution reaching the limit might be a good thing.
If they get a big fat upfront payment maybe they can use some of that to buy back shares on the market. That is a bit unconventional but I know of another pre-revenue biotech that did that recently.
Six degrees to Kevin Bacon. That is how far detectives look in investigating connections between the suspected inside traders and the illegal tipster with access to inside information. That casts a very wide net. While the SEC has fairly limited resources those investigations are conducted by the Justice Department with nearly unlimited resources. Only desperate fools engage in that or career criminals where they obtain the information surreptitiously. Russian mafia types many former KGB agents. Industrial espionage.
All those that have a need to know would be briefed on the confidential nature and will have signed appropriate documents.
There are better legal ways to gain an extremely unfair advantage in the market for a stock.
Ok I admit that was not the best comparable just the most recent. Actual earnings make that apples to oranges. An accretive to earnings typ acquisition and in the rare disease space. What about a cancer drug company with one drug Trodelvy with accelerated provisional approval in TNBC, in use but subject to confirmatory trials. Gilead paid total of $21 billion for Immunomedics.
This raises an open question for some of the more knowledgeable (including you Anders) members of this message board: What are the possibilities of an accelerated approval of DCVAX-L if the results of the interim blinded data hold for the duration and is statistically determined to be a result of the drug?
I did not say I didn't like it. In fact I like it a lot. The fact that NWBO is not concerned with exceeding the authorized share count leads me to believe they may be fairly certain to to have a deal ready to go soon after top line data reporting and publication in a high impact medical journal.
If there is a buyer or partnership with share stake soon once that is inked and before the deal is closed whether by tender offer for the remaining shares or by formal announcement to the public of the partnership stake one would think that Merck or whom ever it is would be briskly buying shares on the open market. That situation would solve to warrant overhang of shares offered for sale because the suitor would absorb all supply of available shares created by warrant holders cashing out. Often when companies are acquired after a Ph 3 success there is a period of a few months when the share price steadily increases then levels off for a few weeks then pop the last time another 40-50 % to the buy out price when the deal is announced.
It is fairly unfathomable to think that there has not been some interests and discussion between NWBO and some BPs.
What was that Alexion BO price?
Seems like a ballpark to consider but with a much larger field.
Well that may be a plausible theory. If so what was the Company's motivation to on May 10, 2020 pursuant to negotiations issue 14.2 million new warrants for a 6 month extension of 81 million warrants or 17.53% more warrants increasing these warrants to 95.2 million for just a 6 month extension to Nov 1st and when the Company did not take any action to increase the authorized share count. They could have held a special shareholder vote within that time frame to increase the authorized shares. So again another 5 million shares to again suspend 178 million warrants 6 weeks to December 15th and no action to increase authorized shares. Unless I am missing something then the fire of having too many warrants which exceed the authorized share count is being attempted to be quelled with the gasoline of issuing millions of more warrants against an already exceeded authorized share limitation.
I believe that the 5 million new warrants given to the holders of the 178 million warrants and options in compensation for the agreement to extend would be identical in strike price and other terms as the existing warrants that were extended. This is from the 8K as those terms were not specified.
Wow! This is huge news. Thank you good work.
Good post. Let us not forget CYDY is the ONLY S2C Phase 3 that got a green light to proceed without changes. All the other trials were either stopped or told the make changes like add more patients at the interim analysis and there are just a very few of those left. That is huge.
The placebo patients get Standard of care I believe.
No that article is not about disclosure of trial results. Any one that bothers to read it will know it is about disclosure of FDA action letters which are now confidential.
If they are in the journal process then both of your points must also be true. That they have seen the data and it is good. You are right they may publish a PR contemporaneous with the internet publication of the pre-publication draft while under final review. Let the naysayers try to attack that because when it does get published essentially the same in the peer reviewed form those that derided it will be swept out to sea in a tidal wave of righteous derision.
As was posted on this board by survivorX earlier today the blinded data already shows astonishing efficacy when compared to historical controls against standard of care.
Coupled with the other post today about the FDA accepting historical controls of SOC then it is clear to see that the heavenly planets are coming into alignment as the "Star of David" one thousand year conjunction of Jupiter and Saturn on the Winter Solstice December 21st in the Western Sky.
The feast has been laid upon the table. Soon is the time to rejoice, rejoice for those suffering from cancer now and in the future. Partake and enjoy but remember why we came to celebrate this feast. Celebrate first for the banishment of the suffering before one celebrates the grace of the gifts this achievement has bestowed upon one's house.
Thank you for bringing into focus the reason for the existence of NWBO. Which is to bring to LIFE a life saving treatment for a nearly hopeless from of Cancer. For DC Vax to play its music it needs to be accepted by the medical community. Therefore the publication is necessary to quiet the negative narrative so it does not interfere or drown out the positive tunes.
Bruce Springsteen was on Fallon show last night and said he and the band tried to do a Zoom like show but could not do it. Without the audience they could not make the music sound right. It did not make sense. They let a group of fans that had gathered outside the studio gates into watch and listen then the feeling was back and they put on a brilliant and inspired show. The audience is the reason to make the music.
The patients best interests MUST come first. They are the reason NWBO has spent all these long years developing their music and the patients and their families are the only ones who will truly appreciate how beautiful that music sounds.
As ae kusterer deduced the most logical reason for the delay in TLD is it will be published in a top peer reviewed medical journal likely with a PR simply stating our TLD is now published in "X" journal with appropriate summary.
This benefits patients most as it will be quicker to be embraced by Doctors and likely receive better handling by regulatory agencies and therefore speed availability.
It will silence the nefarious and otherwise skeptical critics and short sell the news crowd therefore be less distracting to the business of helping the primary beneficiaries, the patients.
All of this will benefit the tertiary beneficiaries the shareholders whether it is published this December or any reasonable month there after.
Putting this in the perspective of what will be the best for those souls with this very aggressive cancer makes the wait not just bearable but sweet.
Putting the patients interests first as it always should be then NWBO has a moral imperative to partner up with a BP that could move the approval process along from here with the greatest speed. Merck is the heavy weight and best suited for cutting edge development in the cancer space. The article in a respected Medical journal gives Merck coverage and leverage to get approval for a deals from its BOD and shareholders.
I definitely think you are on to a likely answer to the riddle. Waiting on the publication benefits everyone most of all the patients as the medical community would pressure the FDA for quick action.
i don't think a stock sale is permissible with an outstanding 10Q. What would they use for the numbers to disclose in the prospectus? Without that how would the SEC grant effectiveness?
The moral of the story is get into a game changing biotech early and hold long term for the ride. How else would a normal individual own a boat load of a Regeneron or Illimina?
Thank you for sharing the email exchange with NWBO Investor Relations. Thinking about what the IR person told you about the timing of TLD release "that would be good for all" there is one aspect that would benefit everyone if it were released after Jan 1 2021. Tax treatment. A huge capital gain in December would create an event with no time to plan for it by taking other losses to offset or otherwise mitigating the tax hit. Also January is widely know as the peak month for mergers and acquisitions. I can only surmise this is for tax planning purposes. So a BO scenario might favor January release as well.
Excellent post regarding setting appropriate expectations.
In regards to other Covid therapeutics other than Leronlimab when CYDY blasts off with EUA or approval or any reason the other companies should enjoy the ride up as well because traders will pile into the next perceived runner. Likely Lenzilumab as it is a mAb but others like Aviptadil as well because it is in a S2C P2b trial.
Case in point Greenwich massive spike on Wednesday and Stella sympathetic jump on Thursday.
Leronlimab has at least 90% chance of approval. Harder to tell with Aviptadil as trial not completed, Leronlimab already has two successful trials but approval of Leronlimab will increase the chance of Aviptadil and other therapies gaining approval when the Regulatory Agencies see the results of Leronlimab against the pandemic and the supplies of Leronlimab run short thereby increasing the focus on other innovations like Aviptadil . But Leronlimab will significantly raise the efficacy for approval bar however there should be plenty of room at the table for other drugs.